NewsBenzingaAcadia Drug Misses Primary Goal in Alzheimer’s Related Psychosis Acadia Drug Misses Primary Goal in Alzheimer’s Related Psychosis Benzinga 2026.09.24 17:43 (GMT+0) Open on Benzinga Other news Reported Earlier, Fresenius Medical Care Launches multiFiltratePRO In US After FDA Clearance, Expanding Continuous Kidney Replacement Therapy Options For Acute Kidney Injury Reported Earlier, Cognizant Agrees To Buy DyFlex Solutions, Strengthening SAP, AI And Enterprise Platform Capabilities In Australia And New Zealand; Terms Not Disclosed Reported Earlier, Supernus Secures Seven Years Of FDA Orphan-Drug Exclusivity For ONAPGO, Seeks Second Supplier Approval By Mid-2027 Barclays Q3 EPS $0.66 Misses $0.67 Estimate, Sales $9.902B Miss $10.180B Estimate Reported Earlier, Workday Prices $2.5B Senior Notes Offering Across Four Tranches, Plans To Retire $1B Of 3.500% Notes Due 2027 Oculis Says Phase 2 ACUITY Biomarker Data Show Privosegtor Lowered NfL, GFAP Versus Placebo In Optic Neuritis, Strengthening Confidence In PIONEER Registrational Program, Exploring Acute MS Relapses
Reported Earlier, Fresenius Medical Care Launches multiFiltratePRO In US After FDA Clearance, Expanding Continuous Kidney Replacement Therapy Options For Acute Kidney Injury
Reported Earlier, Cognizant Agrees To Buy DyFlex Solutions, Strengthening SAP, AI And Enterprise Platform Capabilities In Australia And New Zealand; Terms Not Disclosed
Reported Earlier, Supernus Secures Seven Years Of FDA Orphan-Drug Exclusivity For ONAPGO, Seeks Second Supplier Approval By Mid-2027
Reported Earlier, Workday Prices $2.5B Senior Notes Offering Across Four Tranches, Plans To Retire $1B Of 3.500% Notes Due 2027
Oculis Says Phase 2 ACUITY Biomarker Data Show Privosegtor Lowered NfL, GFAP Versus Placebo In Optic Neuritis, Strengthening Confidence In PIONEER Registrational Program, Exploring Acute MS Relapses
